PMID- 25778308
OWN - NLM
STAT- MEDLINE
DCOM- 20150430
LR  - 20181202
IS  - 1107-0625 (Print)
IS  - 1107-0625 (Linking)
VI  - 20
IP  - 1
DP  - 2015 Jan-Feb
TI  - EGFR mutations in patients with non small-cell lung cancer in Bulgaria and 
      treatment with gefitinib.
PG  - 136-41
AB  - PURPOSE: To evaluate the EGFR mutations in non small cell lung cancer (NSCLC) 
      patients in Bulgaria, as well as to summarize the outcomes of patients with EGFR 
      mutations, treated with gefitinib as first- or subsequent-line therapy. METHODS: 
      From January 2010 to March 2012 tumor samples from773 NSCLC patients were 
      evaluated for EGFR mutations. RESULTS: Seventy-one mutations were found and 34 
      patients were treated with gefitinib. Complete remission (CR) was achieved in 2 
      patients (6.9%), partial remission (PR) in 11 (37.9%), stable disease (SD) in 13 
      (44.8%), and disease progression (PD) in 3 (10.3%). Higher objective response 
      rate was seen in women and in never-smokers.The mean progression-free survival 
      (PFS) was 11.1 months (95% CI 9.1-13.1), registered in 29 patients (median PFS 10 
      months ; 95% CI 8.9-11.1).Tolerability to gefitinib was acceptable, with 
      prevalence of skin toxicity, and it did not lead to any significant decline of 
      the patients' quality of life. CONCLUSION: This is the first study in Bulgaria to 
      evaluate EGFR mutations in NSCLC patients,which were encountered in 9.4% of the 
      studied population. The present study confirms the benefits of first- and 
      subsequent-lines of gefitinib for the treatment of this patient group. Our data 
      give grounds for the conclusion that gefitinib is an effective and well-tolerated 
      therapeutic option for patients with locally advanced and metastatic NSCLC 
      harboring EGFR mutations.
FAU - Damyanov, Danail
AU  - Damyanov D
AD  - Clinic of Medical Oncology, Specialized Oncology Hospital, Sofia, Bulgaria.
FAU - Koynov, Krassimir
AU  - Koynov K
FAU - Naseva, Emilia
AU  - Naseva E
FAU - Bichev, Stoyan
AU  - Bichev S
LA  - eng
PT  - Journal Article
PL  - Cyprus
TA  - J BUON
JT  - Journal of B.U.ON. : official journal of the Balkan Union of Oncology
JID - 100883428
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Quinazolines)
RN  - EC 2.7.10.1 (EGFR protein, human)
RN  - EC 2.7.10.1 (ErbB Receptors)
RN  - S65743JHBS (Gefitinib)
SB  - IM
MH  - Aged
MH  - Antineoplastic Agents/adverse effects/*therapeutic use
MH  - Bulgaria
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/enzymology/*genetics/pathology
MH  - DNA Mutational Analysis
MH  - Disease Progression
MH  - Disease-Free Survival
MH  - ErbB Receptors/*antagonists & inhibitors/*genetics
MH  - Female
MH  - Gefitinib
MH  - Genetic Predisposition to Disease
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Lung Neoplasms/*drug therapy/enzymology/*genetics/pathology
MH  - Male
MH  - Middle Aged
MH  - Molecular Targeted Therapy
MH  - *Mutation
MH  - Patient Selection
MH  - Phenotype
MH  - Precision Medicine
MH  - Predictive Value of Tests
MH  - Protein Kinase Inhibitors/adverse effects/*therapeutic use
MH  - Quinazolines/adverse effects/*therapeutic use
MH  - Remission Induction
MH  - Risk Factors
MH  - Time Factors
MH  - Treatment Outcome
EDAT- 2015/03/18 06:00
MHDA- 2015/05/01 06:00
CRDT- 2015/03/18 06:00
PHST- 2015/03/18 06:00 [entrez]
PHST- 2015/03/18 06:00 [pubmed]
PHST- 2015/05/01 06:00 [medline]
PST - ppublish
SO  - J BUON. 2015 Jan-Feb;20(1):136-41.